Quantbot Technologies LP Cuts Stake in LivaNova PLC $LIVN

Quantbot Technologies LP lowered its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 25.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,689 shares of the company’s stock after selling 7,911 shares during the period. Quantbot Technologies LP’s holdings in LivaNova were worth $1,188,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the stock. Envestnet Asset Management Inc. grew its stake in LivaNova by 168.1% during the third quarter. Envestnet Asset Management Inc. now owns 27,125 shares of the company’s stock valued at $1,421,000 after acquiring an additional 17,007 shares in the last quarter. Allianz Asset Management GmbH purchased a new stake in LivaNova in the 3rd quarter worth $7,687,000. LSV Asset Management lifted its stake in LivaNova by 25.4% in the 3rd quarter. LSV Asset Management now owns 674,610 shares of the company’s stock worth $35,336,000 after purchasing an additional 136,600 shares in the last quarter. Emerald Mutual Fund Advisers Trust boosted its holdings in shares of LivaNova by 8.1% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 349,664 shares of the company’s stock valued at $18,315,000 after purchasing an additional 26,202 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in shares of LivaNova by 79.6% during the 2nd quarter. New York State Common Retirement Fund now owns 86,741 shares of the company’s stock valued at $3,905,000 after purchasing an additional 38,451 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on LIVN. Piper Sandler reaffirmed an “overweight” rating and issued a $85.00 target price on shares of LivaNova in a report on Thursday, February 19th. Mizuho boosted their target price on LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d+)” rating on shares of LivaNova in a research note on Monday, December 29th. Stifel Nicolaus set a $80.00 price target on LivaNova in a report on Wednesday, February 25th. Finally, Barclays lifted their price objective on LivaNova from $67.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Seven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $74.78.

LivaNova Stock Down 1.3%

Shares of LIVN opened at $63.84 on Friday. The company has a quick ratio of 1.16, a current ratio of 1.36 and a debt-to-equity ratio of 0.29. The business has a fifty day moving average of $65.08 and a 200 day moving average of $59.51. The company has a market cap of $3.49 billion, a PE ratio of -14.31 and a beta of 0.92. LivaNova PLC has a 52-week low of $32.48 and a 52-week high of $71.92.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.80 by $0.06. The business had revenue of $360.86 million for the quarter, compared to the consensus estimate of $354.31 million. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The business’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.81 earnings per share. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. On average, sell-side analysts expect that LivaNova PLC will post 2.85 EPS for the current year.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.